Monday, December 14, 2009 - 07:00
Reinach, Switzerland, 14 December 2009 – Evolva Holding SA (SIX: EVE) (formerly known as Arpida Ltd.) today announced the final closing of its Series B financing round, the completion of its merger with Evolva SA, the change of the name from Arpida Ltd. to Evolva Holding SA and the listing of its shares issued in connection with the merger.
Thursday, November 26, 2009 - 07:00
Reinach, Switzerland, 26 November 2009. The Extraordinary General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors.
Wednesday, November 4, 2009 - 07:00
Arpida Ltd. (SIX: ARPN) has today announced that Evolva and Arpida have entered into a definitive agreement to combine their businesses. The combination agreement sets out the details of the proposed transaction and has been approved by the Boards of Directors of both companies. The combination is subject to the satisfaction of certain closing conditions such as approval by the Arpida shareholders.
Thursday, October 29, 2009 - 07:00
Basel, Switzerland, 29 October 2009 – Evolva SA, a Swiss headquartered international biotech company has expanded its management team by appointing Jessica Mann as Chief Medical Officer. She has supported Evolva as an advisor over the last year and has been actively involved in the clinical development of Evolva’s compound portfolio in this period.
Thursday, October 22, 2009 - 07:00
Basel, Switzerland, 22 October 2009 – Evolva SA, a Swiss headquartered international biotech company today announced a CHF 28 million first closing of its Series B financing round. The Series B financing is led by current investor Aravis and new investors Auriga Partners, Vinci Capital – Renaissance PME and Wellington Partners. BioMedInvest and an undisclosed private investor participated as co-investors in the first closing, as well as Evolva's existing investors Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital.
Thursday, September 10, 2009 - 07:00
Reinach/Allschwil, Switzerland, 10 September 2009. Arpida Ltd. (“Arpida”) and Evolva SA (“Evolva”), two Swiss biotech companies, today announced that they intend to merge the two companies subject to definitive agreement and shareholder approval. Arpida is listed on the Swiss stock exchange (SIX Swiss Exchange: ARPN) while Evolva is a privately-held company with headquarters near Basel and operations in Denmark, USA and India. The intended merger creates a company with promising growth prospects based on a pipeline of clearly differentiated drug candidates addressing major medical needs and a number of discovery partnerships generating significant revenues.
Thursday, August 27, 2009 - 07:00
Basel, Switzerland, 27th August 2009 – Evolva SA, a Swiss headquartered international biotech company has expanded its Management team by appointing Jutta Heim as Chief Technology Officer. In her new role, Jutta Heim will lead Evolva’s discovery activities and strengthen the development of our technology platform.
Thursday, July 16, 2009 - 07:00
Basel, Switzerland, 16th July 2009 – Evolva SA, a Swiss headquartered international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has completed a single ascending dose Phase I clinical trial in healthy volunteers with EV-077–3201–2TBS.
Wednesday, March 18, 2009 - 07:00
Basel, Switzerland, 18 March 2009 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has started Phase I Clinical Trials with its drug candidate EV-077–3201–2TBS.
Tuesday, January 6, 2009 - 07:00
Basel, Switzerland – January 2009 – Evolva SA, an international biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, is pleased to announce that it has entered into an exclusive worldwide licensing agreement with the UK Company, Summit Corporation plc (“Summit”). The agreement covers EV-009–4400 (SMT 14400), a second generation imino sugar, which is being developed as potential treatments for infectious diseases associated with bio-terrorism.
